BioAge Labs (BIOA) Income towards Parent Company (2023 - 2026)
BioAge Labs' (BIOA) quarterly Income towards Parent Company came in at -$25.9 million in Q2 2026, down 20.16% year-over-year from -$32.4 million in Q2 2025, and down 16.93% quarter-over-quarter from -$22.1 million in Q1 2026.
Analysis
BioAge Labs (BIOA) Income towards Parent Company (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Income towards Parent Company across 4 years of filings, most recently posting -$25.9 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 20.16% year-over-year to -$25.9 million; the TTM figure through Jun 2026 stood at -$93.9 million (down 18.51% YoY), while the FY2025 annual figure was -$80.4 million, down 13.34% from the prior year.
- Income towards Parent Company came in at -$25.9 million for Q2 2026 at BioAge Labs, down from -$22.1 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$11.8 million in Q3 2023 to a low of -$25.9 million in Q2 2026.
- Average Income towards Parent Company over 4 years is -$18.9 million, with a median of -$20.8 million recorded in 2025.
- Year-over-year, Income towards Parent Company tumbled 95.92% in 2024 and climbed 12.87% in 2025.
- Over 4 years, Income towards Parent Company stood at -$15.8 million in 2023, then tumbled by 36.83% to -$21.6 million in 2024, then decreased by 19.17% to -$25.7 million in 2025, then fell by 0.67% to -$25.9 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$25.9 million in Q2 2026, -$22.1 million in Q1 2026, and -$25.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.90 Mn |
| Mar 31, 2026 | -22.15 Mn |
| Dec 31, 2025 | -25.72 Mn |
| Sep 30, 2025 | -20.13 Mn |
| Jun 30, 2025 | -21.55 Mn |
| Mar 31, 2025 | -12.99 Mn |
| Dec 31, 2024 | -21.59 Mn |
| Sep 30, 2024 | -23.10 Mn |
| Jun 30, 2024 | -13.51 Mn |
| Mar 31, 2024 | -12.73 Mn |
| Dec 31, 2023 | -15.78 Mn |
| Sep 30, 2023 | -11.79 Mn |